SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dick's Sporting Goods, Inc. engages in the retailing of an extensive assortment of authentic sports equipment, apparel, footwear, and accessories. It also offers its products both online and through mobile applications. The company was founded by Richard T. Stack in 1948 and is headquartered in Coraopolis, PA.

Dicks Sporting Goods, Inc.

DKS shares are getting slammed after a brutal Q2 earnings miss and steep full-year guidance cut, amplifying fears tied to the Foot Locker acquisition and a deteriorating athletic footwear market. Traders are fiercely split, with many dismissing the ~30% crash as an extreme overreaction and an oversold entry point, while others warn of a falling knife as analysts slash price targets and question the company's strategic direction.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

RIGL is surging as investors react to the company's exclusive global licensing agreement for VEPPANU, the first FDA-approved PROTAC therapy for breast cancer, which analysts and shareholders view as a major growth catalyst that could transform the company's commercial portfolio. The buzz centers on the drug's large market potential and the belief that the stock is significantly undervalued, with retail traders pointing to high short interest as fuel for a potential squeeze.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

SMMT is trending as investors weigh the recent NMPA approval for ivonescimab in China against a $500M dilutive offering and the looming FDA PDUFA on Nov 14, while CEO insider buying and positive phase 3 data keep bulls optimistic and bears questioning Western efficacy and the FDA's OS bar.

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is trending as the biotech community debates its FDA-approved IgAN drug Trutakna, with discussions centered on competitive positioning against Otsuka's rival therapy, persistent short interest, and speculation over a potential buyout or upcoming clinical data. Community sentiment remains divided between concerns about competition and conviction in the drug's efficacy and the company's undervaluation.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is trending as traders position into its upcoming earnings report, with the community focused on extreme valuation gaps versus CrowdStrike and Palo Alto Networks, heavy bullish call/put activity, and persistent M&A speculation around a potential big-tech buyout.

McDonald's Corp. engages in the operation and franchising of restaurants. The firm operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. Its products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, and McCafe beverages. The company was founded by Raymond Albert Kroc on April 15, 1955 and is headquartered in Chicago, IL.

McDonald`s Corp

McDonald's Corp

MCD is under heavy selling pressure after hitting a 52-week low, with the StockTwits community deeply divided between bears calling for further downside and bargain hunters seeing a defensive entry point. Sentiment is dominated by frustration over weak price action and questions about consumer spending, though some traders are citing bullish divergences and noting the stock's status as a defensive haven amid broader market volatility. The move is being tied to sector-wide concerns about consumer health and restaurant demand, with a notable Elliott Wave analysis pointing to further potential downside.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

CRML is surging with the rare-earth sector as U.S. government funding for critical minerals and progress at its Tanbreez project drive a wave of bullish retail sentiment, with traders eyeing a potential short squeeze.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is dominating retail chatter as the market holds its breath for the company's upcoming earnings report, with traders split on whether a massive beat and raised guidance can finally break the stock's persistent post-earnings sell-off pattern. Simultaneously, the community is closely monitoring the competitive threat from OpenAI's custom 'Jalapeno' chip, which just posted performance-per-watt gains over Nvidia's Blackwell architecture.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as the stock surges off post-earnings lows, breaking above recent resistance on bullish analyst reiterations and optimism around its autonomous vehicle partnerships. Traders are also watching the $80 level as a key battleground, with the Dutch GDPR fine failing to derail momentum.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

IMMX is ripping to fresh all-time highs as retail traders position aggressively ahead of the highly anticipated NXC-201 topline data, with the community buzzing over the drug's stellar 95% complete response rate and the potential for a lucrative buyout. The prevailing sentiment is that a massive short squeeze is imminent given the tight float, heavy 9.5M short positions, and a recent wave of bullish analyst coverage tracking the broader Big Pharma appetite for similar late-stage biotech assets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AQST is trending as retail investors closely monitor the anticipated NDA resubmission for Anaphylm, viewing it as a near-term catalyst for a potential price breakout. The community's sentiment is a mix of bullish conviction on the drug's differentiated profile versus competitors and frustration over the stock's recent price suppression and management's perceived communication gaps.

Aquestive Therapeutics Q2 Earnings Call Highlights

Aquestive Therapeutics Q2 Earnings Call Highlights...

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -80.00% and +12.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study

Aquestive Therapeutics reports positive study results for Anaphylm sublingual film, paving the way for a Q3 FDA resubmission.read more...

Guardian Pharmacy Services (GRDN) Q2 Earnings and Revenues Top Estimates

Guardian Pharmacy (GRDN) delivered earnings and revenue surprises of +11.54% and +3.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?

Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Aquestive Therapeutics Q1 Earnings Call Highlights

Aquestive Therapeutics Q1 Earnings Call Highlights...

Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +50.00% and +33.22%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -0.82% and +42.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Why Did AQST Stock Jump 35% Today?

Equity

Neutral Sentiment

Rallies more than 5%

Modest gain (0-5%)

Modest decline (0-5%)

Drops more than 5%

Nvidia ($NVDA) reports earnings Wednesday, August 26, with options markets pricing in a roughly 5-7% post-earnings move. How do you think Nvidia's stock reacts to earnings? Vote and explain your reasoning in the comments.

Nvidia ($NVDA) reports earnings Wednesday, with options markets pricing in a 5-7% move. How do you think the stock reacts?

Stocktwits

) reports earnings Wednesday, with options markets pricing in a 5-7% move. How do you think the stock reacts?

Feed

News

Sentiment

Earnings

Fundamentals

Info

AQST Aquestive Therapeutics Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest AQST News